Blinatumomab or Inotuzumab Ozogamicin as Bridge to Allogeneic Stem Cell Transplantation for Relapsed or Refractory B-lineage Acute Lymphoblastic Leukemia: A Retrospective Single-Center Analysis
Publication date: October 2020Source: Clinical Lymphoma Myeloma and Leukemia, Volume 20, Issue 10Author(s): Patrick Stelmach, Klaus Wethmar, Christoph Groth, Daniela V. Wenge, Jörn Albring, Jan-Henrik Mikesch, Christoph Schliemann, Christian Reicherts, Wolfgang E. Berdel, Georg Lenz, Matthias Stelljes
era J Abstract The decision to incorporate allogeneic hematopoietic stem cell transplant (allo-HSCT) into front-line therapy in adult acute lymphoblastic leukemia (ALL) should be primarily guided by measurable residual disease (MRD) status and the ALL regimen utilized. While there is no doubt that allo-HSCT benefits patients with poor MRD response after induction or consolidation, the indication of allo-HSCT in cases of good MRD clearance is not clear. As targeted immunotherapies result in high MRD-negative CR rates, early incorporation of these therapies may also prove valuable in reducing the need for HCT in the...
The effect of post-transplant ponatinib maintenance therapy on outcomes after allogeneic hematopoietic stem cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia has remained unknown. The presented results suggest that survival in the ponatinib group was better than that in the non –ponatinib group and that ponatinib maintenance therapy is safe. The post-transplant ponatinib maintenance strategy might be promising.
The impact of post-transplant ponatinib maintenance therapy on outcomes after allogeneic hematopoietic stem cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia remains still unknown. This retrospective study suggested that survival in the ponatinib group was better than that in non-ponatinib group and ponatinib maintenance therapy was safety. The post-transplant ponatinib maintenance strategy might be promising.
Publication date: Available online 3 June 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Patrick Stelmach, Klaus Wethmar, Christoph Groth, Daniela V. Wenge, Jörn Albring, Jan-Henrik Mikesch, Christoph Schliemann, Christian Reicherts, Wolfgang E. Berdel, Georg Lenz, Matthias Stelljes
In the present report, we have described the clinical course of 34 adult patients who had received blinatumomab or inotuzumab ozogamicin for relapsed or refractory acute lymphoblastic leukemia. Both agents induced high rates of molecular complete remission, with manageable toxicity profiles, allowing 80% of transplantable patients to proceed to allogeneic stem cell transplantation. These data suggest high efficacy and safety for both drugs in a bridge-to-transplantation setting.
Here, we report the clinical course of 34 adult patients receiving Blinatumomab or Inotuzumab ozogamicin for relapsed or refractory acute lymphoblastic leukaemia. Both agents induced high rates of (molecular) complete remissions and showed manageable toxicity profiles, allowing 80% of transplantable patients to proceed to allo-SZT. These data suggest a high efficacy and safety of both drugs in a bridge-to-transplant setting.
AbstractThe introduction of chimeric antigen receptor T cell (CAR T) therapy has resulted in a paradigm shift in the management of relapsed/refractory B cell malignancies. Patients with acute lymphoblastic leukemia and non ‐Hodgkin’s lymphoma who had exhausted all meaningful treatment options now have an opportunity for long‐term remission and possibly cure. CAR T is rapidly expanding into the treatment paradigm for multiple myeloma with approvals expected in the near future. CAR T for chronic lymphocytic leukem ia may not be far behind, while CAR T studies in Hodgkin lymphoma and acute myeloid leukemia are ongoi...
Currently, effective and safe salvage therapies are limited among patients with relapsed B-cell acute lymphoblastic leukemia (B-ALL) after allogeneic hematopoietic stem-cell transplantation (allo-HSCT). Eleven patients with B-ALL that relapsed after allo-HSCT were treated with a single infusion of donor-derived anti-CD19 chimeric antigen receptor T (CAR T) cells. Eight patients (72.7%) experienced morphologic remissions; 7 (63.6%) experienced minimal residual disease –negative remission. Allogeneic donor-derived anti-CD19 CAR T cell is an effective and safe salvage method for patients with relapsed/refractory B-ALL after allo-HSCT.
The treatment of adult acute lymphoblastic leukemia in the safety-net hospital setting has been heterogeneous given the lack of standardized guidelines. We retrospectively analyzed the outcomes of 90 ALL patients treated at Harbor-UCLA Medical Center, a public hospital in Los Angeles County which lacks the capacity for therapeutic clinical trials and stem cell transplantation. Referral of patients with high risk features to a transplant center may lead to improved survival.
Chimeric antigen receptor (CAR) T cell immunotherapy has been a major advancement in cancer therapeutics. Reprogramming of T cells is achieved by using gammaretroviral or lentiviral vectors, which may interfere with human immunodeficiency virus type 1 (HIV-1) nucleic acid amplification testing (NAAT). Here, we describe three clinical scenarios in which CAR T cell immunotherapy interfered with HIV-1 testing, including (i) routine infectious disease screening prior to stem cell transplantation in a 16-year-old female with B cell acute lymphoblastic leukemia, post CAR T cell treatment; (ii) routine infectious disease screenin...